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Abstract 
Background: Alterations in glucose metabolism that lead to the development of metabolic and 
cardiovascular disease may begin already in childhood.  
Objective: This study aims to generate pediatric age and sex-specific reference values for fasting 
concentrations of glucose, HbA1c, insulin, C-peptide, and HOMA-IR in Danish/North-European 
white children and adolescents from a population-based cohort and to compare values from children 
and adolescents with overweight/obesity with this reference. 
Methods: The population- and obesity clinic-based cohorts consisted of 2,451 and 1,935 children 
and adolescents between 6-18 years of age. Anthropometric measurements and blood samples were 
obtained and percentile curves were calculated. 
Results: In the population based-cohort, glucose, insulin and HOMA-IR values increased before the 
expected onset of puberty (P<0.05). Thereafter, all variables decreased in girls (P<0.05) and HbA1c 
decreased in boys (P<0.05). Concentrations of all measured markers of glucose metabolism were 
higher in the obesity clinic-based cohort than the population-based cohort (both sexes P<0.001). 
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Specifically, insulin and HOMA-IR continued to increase to 18 years in the clinic-based cohort, 
particularly among boys. 
Conclusions: Fasting glucose, insulin, and HOMA-IR change during childhood, making pediatric 
reference values essential for timely identification of derangements in glucose metabolism. Children 
and adolescents with obesity exhibit increased concentrations of these biomarkers.  
 
Main text 
 
Introduction 
Alterations in glucose metabolism are important in the development of metabolic and 
cardiovascular disease 1–3 and may occur already in childhood. With the presence of childhood 
obesity 4, these alterations become increasingly common 5,6. Though the prevalence of type 2 
diabetes in children and adolescents is less than 1%, the prevalence is estimated to quadruple by 
2050, mainly driven by the rising obesity rates 7,8 while prediabetes is already common 6,9. 
Prediabetes is broadly defined as an altered glucose metabolism that is still below the diabetes 
threshold 2,10. In adults with prediabetes, 30-40% will progress to manifest type 2 diabetes within a 
few years without intervention 11 and this transition has been reported to be even more rapid in 
children and adolescents 12. 
Among children and adolescents with type 2 diabetes, the prevalence of obesity is much higher than 
in adults with type 2 diabetes 13, and there is a strong inverse association between BMI and age at 
onset of type 2 diabetes 14. Therefore, focused efforts should be made in children and adolescents 
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with overweight/obesity to detect early alterations in glucose metabolism in order to begin timely 
interventions and furthermore to make preventive efforts. 
Cardiovascular and metabolic risk factors vary with age, sex, ethnicity, and puberty stage 15. This 
includes biochemical markers of glucose metabolism, emphasizing the importance of appropriate 
pediatric reference values for the physician. Different pediatric reference values for fasting 
concentrations of glucose, HbA1c, insulin, and HOMA-IR have been suggested in the literature 16–19 
and especially fasting glucose has been shown to vary across populations 18. Furthermore, 
concentrations of HbA1c were higher in a pre-pubertal combined European population compared to 
a Scandinavian population 16 supporting the need for establishing references values in regional and 
homogenous populations.  
Our study contributes with age- and sex-specific reference values for glucose, HbA1c, insulin, C-
peptide, and HOMA-IR in a homogenous population of Danish/North-European white children and 
adolescents. In addition, we present differences in these markers of glucose metabolism between the 
population-based cohort and children and adolescents with overweight/obesity.   
 
Methods 
Study populations 
Two cohorts of children and adolescents were included in the study: 1) A population-based cohort 
and 2) a cohort with overweight/obesity. 
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The population-based cohort (N= 2,898) is based on children and adolescents recruited from 
October 2010 to February 2015 from schools across 11 municipalities in the region of Zealand and 
the Capital region in Denmark. Additionally, pre-school children were recruited from March 2015 
to March 2016 from the public dentistry and health care nurses in one municipality in the region of 
Zealand. This cohort has previously been described 20,21. 
The exclusion criteria for the population-based cohort were: 1) age younger than 6.0 or older than 
18.9 years (N=124); 2) no available blood sample data (N=3); 3) more than 30 days between the 
clinical examination and the blood sample (N=95); 4) ethnicity other than Danish/North European 
white (N=220); 5) diagnosed type 1 diabetes (N=4); 5) diagnosed type 2 diabetes  (N=0); 7) intake 
of insulin, Liraglutid, or metformin (N=0), and 8) meeting type 2 diabetes criteria on the blood 
sample (fasting plasma glucose>7.0 mmol/l and/or HbA1c > 49 mmol/mol) (N=1). 
The cohort of children and adolescents with overweight/obesity (N=2,873) was recruited from 
January 2009 to June 2018 from The Danish Childhood Obesity Biobank, prior to the patients’ 
commencement of a multidisciplinary outpatient treatment program 22,23. Applying identical 
exclusion criteria as for the population-based cohort, the following exclusions were made: 1) age 
(N=148); 2) no blood sample data (N=6); 3) more than 30 days between the clinical examination 
and the blood sample (N=464); 4) ethnicity (N=305); 5) diagnosed type 1 diabetes (N=7); 6) 
diagnosed type 2 diabetes (N=2); 7) medication (N=3), and 8) meeting type 2 diabetes criteria on 
the blood sample (N=3). 
Outcome measures  
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Phenotyping was performed by trained medical staff and involved an extensive systemized 
questionnaire, a clinical examination and a fasting venous blood sample. For the population-based 
cohort, the questionnaire was completed at home before the examination. For the cohort with 
overweight/obesity, the questionnaire was completed by interview with a nurse or a pediatrician. 
Fasting samples of plasma glucose, whole blood HbA1c, serum insulin, and serum C-peptide were 
obtained. HOMA-IR was used in this study as a surrogate marker for insulin sensitivity and was 
calculated as insulin (mIU/L) x glucose (mmol/L)/22.5 24 with a conversion factor of 6.00 between 
insulin in μU/L and mmol/L 25. 
Anthropometric measurements 
Anthropometric measurements were performed while wearing light indoor clothes and no shoes. 
Height was measured by stadiometer to the nearest 1 mm and weight was measured to the nearest 
0.1 kg on a Tanita® BC418 Scale (Tanita Corp., Japan) in the population-based cohort, and on a 
Tanita® Digital Medical Scale, WB-110 MA (Tanita Corp., Japan) in the cohort with 
overweight/obesity. BMI SDS was calculated using the LMS method 26 according to Danish BMI 
charts 27.  
Puberty stage 
The puberty stage was assessed according to the Tanner classification 28,29. In the population-based 
cohort, puberty was self-evaluated using a questionnaire with picture pattern recognition. In the 
cohort with overweight/obesity, a pediatrician evaluated the puberty stage. Self-evaluated puberty 
staging has been shown adequate for discriminating between pre-pubertal and pubertal stages 30. 
Consequently, puberty stage in both the population-based cohort and the cohort with 
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overweight/obesity was defined as pre-pubertal (Tanner 1) or pubertal (Tanner 2-5) in the present 
study.  
 
Blood samples 
The blood samples were obtained from venipuncture of the antecubital vein between 7 and 9 AM 
after an overnight fast. If requested, the venipuncture was performed after application of a local 
anesthetic (lidocaine/prilocaine mixture, EMLA®, AstraZeneca, Sweden).  
Plasma glucose concentrations (intra- and inter-assay coefficients of variation (CV): 2.3% and the 
detection limits (DL): 0.06 mmol/L) were determined on a Dimension Vista® 1500 Analyser 
(Siemens, Germany). Serum insulin concentrations (CV: 2.0% and DL: 1.4 pmol/L) and C-peptide 
concentrations (CV: 3.4% and DL: 0.003 nmol/L) were analyzed on a Cobas® 6000 Analyser 
(Roche Diagnostics, Germany). Whole-blood HbA1c (CV: 1.9% and DL: 24.6 mmol/mol) was 
analyzed on a Tosoh high-performance liquid chromatography G8 analyser (Tosoh Corporation, 
Japan). 
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Data Protection Agency. The study was carried out in accordance with the Helsinki Declaration of 
1975 as revised in 2013.   
Statistics  
Statistical analyses were performed in R statistical software (v.3.5.1) 32. Age- and sex-specific 
percentiles and percentile curves were calculated using the Generalized Additive Models for 
Location Scale and Shape (GAMLSS) package 33, using the Box–Cox transformation distribution 
family. To investigate effects of age within each sex, the participants were allocated into three 
groups: 6.0-9.9, 10.0-14.9, and 15.0-18.9 years of age. These age intervals were chosen to 
approximate periods of pre-puberty, puberty, and post-puberty respectively 34, as puberty stage was 
only available in a subset of children and adolescents. Each sex was analyzed separately and 
normality of data was evaluated using histograms and qq plots. Differences between cohorts were 
examined using Student’s t-test or Wilcoxon rank sum test. Differences in concentrations of 
biomarkers and HOMA-IR between age groups were examined using Kruskal-Wallis test and 
pairwise Wilcoxon rank sum tests. Multiple comparisons were controlled for by the Holm’s 
method. A generalized linear regression model was used to investigate effects of puberty for each 
sex adjusted for age and BMI SDS. Potential interactions between pubertal stage and biomarkers 
and HOMA-IR were investigated. A P<0.05 was considered statistically significant.  
 
Results 
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From the population-based cohort, 2,451 (1,452 girls) children and adolescents with a median age 
of 11.5 years were included in the study. Of these, 5.9% (N=144) exhibited underweight (BMI<10th 
percentile) and 17.7% (N=435) exhibited overweight/obesity (BMI>90th percentile) according to 
Danish reference values 27. From the cohort with overweight/obesity (all: BMI>90th percentile), 
1,935 (1,050 girls) children and adolescents with a median age of 11.8 years were included in the 
study. The descriptive data for the two cohorts are shown in Table 1. The age distribution by sex for 
each 1-year age stratum for both cohorts is shown in Supplementary Table S1. 
Relation to age and sex in the population-based cohort 
Age- and sex-specific reference values for glucose, HbA1c, insulin, and HOMA-IR from the 
population-based cohort are presented as percentile curves in Figure 1 and percentile reference 
tables in Supplementary Table S2. Changes in C-peptide mirror the changes in insulin and will not 
be presented further in results. Reference curves for C-peptide are presented in Supplementary 
Figure S1. 
Table 2 shows the population-based cohort divided into age groups. From the youngest (6.0-9.9 
years) to the intermediate age group (10.0-14.9 years) glucose, insulin, and HOMA-IR increased in 
both girls and boys, while HbA1c increased in only boys (all P<0.001). From the intermediate to the 
oldest age group (15.0-18.9 years) the sexes differed: in girls, glucose, HbA1c, insulin, and HOMA-
IR all decreased (P<0.01); in boys, only HbA1c decreased (P<0.001). Figure 1 similarly illustrates 
how glucose, insulin, and HOMA-IR peak around expected pubertal maturation 34, corresponding to 
age ~13 years for girls and ~15 years for boys.  
Characteristics of participants in the highest percentiles from the population-based cohort  
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Compared to the rest of the population-based cohort, participants with glucose values above the 90th 
percentile exhibited a 0.4 points higher BMI SDS (P<0.001). Participants with insulin and HOMA-
IR above the 90th percentile both exhibited a 1.0 points higher BMI SDS (both P<0.001), while no 
difference was found for participants with HbA1c above the 90th percentile, compared to the rest of 
the population. Overall 24.6% of the population had values of one or more of these biomarkers 
above the 90th percentile, while only 2.6% had values above the 90th percentile for both glucose and 
insulin.  
Comparison between the population-based cohort and the cohort with overweight/obesity 
Reference values for glucose, HbA1c, insulin, and HOMA-IR from the cohort with 
overweight/obesity are presented as percentile curves in Figure 2 and percentile reference tables in 
Supplementary Table S3.  
Table 2 also shows the cohort with overweight/obesity divided into age groups. Glucose, insulin, 
and HOMA-IR increased from the youngest to the intermediate age group in both girls and boys 
(P<0.001). The changes from the intermediate to the oldest age group differed from the pattern 
observed in the population-based cohort: in girls, only HbA1c decreased (P=0.023), whereas 
glucose, insulin and HOMA-IR remained unchanged; in boys, glucose, insulin, and HOMA-IR all 
increased (P<0.005) compared with no change in the population-based cohort.  
When comparing the two cohorts, the median age in the cohort with overweight/obesity was higher 
in the youngest age group and lower in the oldest age group than the population-based cohort 
(P<0.05). As expected, BMI SDS was higher in the cohort with overweight/obesity compared with 
the population-based cohort in all age groups (P<0.001).  
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Insulin and HOMA-IR were higher in the cohort with overweight/obesity compared with the 
population-based cohort in all age groups (P<0.001) (see Table 2). Glucose was higher in the 
youngest and oldest age group (P<0.005), but similar in the intermediate age group compared with 
the population-based cohort. HbA1C was higher only in the oldest age group of boys in the cohort 
with overweight/obesity compared with the population-based cohort (P=0.012). 
Figure 2 compares percentile curves for the 5th, 50th, and 95th percentiles of the biomarkers between 
the two cohorts and illustrates marked differences. For insulin and HOMA-IR, the rise towards the 
described peak around pubertal maturation occurred at an earlier age in the cohort with 
overweight/obesity. For girls, these concentrations remained high thereafter, whereas for boys, they 
increased even further. Glucose and HbA1C showed a comparable, but less pronounced, pattern in 
the boys with overweight/obesity. 
Relation to puberty stage  
Data on puberty stage was available in 80.0% (N=1161) of girls and in 58.8% (N=587) of boys in 
the population-based cohort. When adjusting for age and BMI SDS, puberty compared with pre-
puberty in girls was associated with 0.27 mmol/L higher concentrations of glucose ([95% 
CI:0.20;0.34], P<0.001); 0.49 mmol/mol higher concentrations of HbA1C ([95% CI:0.00;0.98], 
P=0.048); 21.7 pmol/L higher concentrations of insulin ([95% CI:16.4;26.9], P<0.001); and 0.94 
mIU/L higher HOMA-IR ([95% CI:0.72;1.16], P<0.001). When adjusting for age and BMI SDS, 
puberty compared with pre-puberty in boys was associated with 0.09 mmol/L higher concentrations 
of glucose ([95% CI:0.01;0.18], P=0.024); and interactions were identified such that the association 
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between BMI SDS and insulin was 4.0 pmol/L higher per BMI SDS in pubertal than pre-pubertal 
boys ([95% CI:0.1;8.0], P=0.047). 
Data on puberty stage was available in 85.0% (N=893) of girls and in 75.1% (N=665) of boys in the 
cohort with overweight/obesity. When adjusting for age and BMI SDS in girls in the cohort with 
overweight/obesity, puberty compared with pre-puberty was associated with 0.13 mmol/L higher 
concentrations of glucose ([95% CI:0.04;0.22], P=0.006). For the other biomarkers interactions 
were identified such that the association between BMI SDS and HbA1c was 1.44 mmol/mol higher 
per BMI SDS in pubertal than pre-pubertal girls ([95% CI:0.65;2.23], P<0.001); the association 
between BMI SDS and insulin was 32.8 pmol/L higher per BMI SDS ([95% CI:14.0;51.6], 
P<0.001); and the association between BMI SDS and HOMA-IR was 1.18 mIU/L higher per BMI 
SDS ([95% CI:0.60;1.77], P<0.001). In boys in the cohort with overweight/obesity, interactions 
were identified such that the association between BMI SDS and insulin was 31.8 pmol/L higher per 
BMI SDS in pubertal than pre-pubertal boys ([95% CI:4.7;58.8], P=0.022); and the association 
between BMI SDS and HOMA-IR was 1.46 mIU/L higher per BMI SDS ([95% CI:0.18;2.74], 
P=0.025).   
These interactions were not present in girls in the population-based cohort, and while an interaction 
was present in boys in the population-based cohort for insulin, it showed an 8-fold lower effect than 
in the cohort with overweight/obesity (²  = 4.0 vs. ²  = 31.8). 
Discussion 
We generated age- and sex-specific reference values for fasting blood concentrations of glucose, 
HbA1c, insulin, C-peptide, and the HOMA-IR index from a large population-based cohort of 
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Danish/Northern European white children and adolescents aged 6.0-18.9 years and demonstrated 
that these markers of glucose metabolism vary significantly during childhood and adolescence. We 
further examined how the concentrations of these markers in a cohort of children and adolescents 
with overweight/obesity compared with the established reference. 
Our presented references values are in accordance with the existing literature 16,17,19,35. The 
IDEFICS study by Peplies et al. presented reference values for 7,074 pre-pubertal children with 
normal weight and ages of 3.0–10.9 years from eight European countries and showed that fasting 
glucose, insulin, and HOMA-IR increase with age 16. The HELENA study by Koester-Weber et al 
calculated reference values for fasting glucose and insulin in 927 adolescents aged 12.5–17.4 years 
from nine European countries and showed stable glucose values and deceasing insulin values with 
age 17. Most adolescents in the HELENA study were classified as Tanner 4 or 5. Our study included 
both pre-pubertal, pubertal, and post-pubertal children and adolescents, and we observed both a 
significant increase in these biomarkers with age before expected onset of puberty, similar to the 
IDEFICS study, and a significant decrease (mainly in girls) or a plateau in these biomarkers with 
age after expected puberty, similar to the HELENA study 17. We observed a 45–50% increase in 
median HOMA-IR from age 10 to 14 years in both girls and boys. This phenomenon of relative 
pubertal insulin resistance is well known, and an approximate 30% reduction in estimates of insulin 
sensitivity during mid-puberty has previously been reported 36,37.  Interestingly, while insulin levels 
rose sharply during puberty, fasting glucose was only minimally affected in the present study, 
probably due to an adequate ability to increase insulin production.  
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When comparing the two cohorts, we found that the cohort with overweight/obesity was affected in 
their markers of glucose metabolism: glucose was higher in the youngest and oldest age group, 
whereas insulin and C-peptide concentrations as well as HOMA-IR were higher in all age groups. 
This is similar to the findings in the IDEFICS study, where a strong dependency on weight status 
was observed for insulin and HOMA-IR but not glucose 16. The HELENA study and Koester-
Weber et al. also showed a positive association between BMI and insulin and they did not detect an 
association with glucose 17. However in contrast to the present study, these two studies did not 
include entire cohorts with overweight/obesity, as they considered solely the participants from their 
population-based samples with overweight/obesity and as such might be underpowered to detect the 
associations for fasting glucose.  
In a sub analysis of the population-based cohort with values above the 90th percentile for each 
biomarker, we found that these participants had a significantly higher BMI SDS, especially for 
insulin and HOMA-IR. We further found that only a very small proportion of the population had 
high values of both glucose and insulin. While normal variations in markers of glucose metabolism 
are complex, these results indicate that also in a population-based pediatric sample, increased 
weight affects glucose metabolism mainly through increased insulin resistance matched by an 
increased insulin production. 
In our population-based cohort, puberty compared with pre-puberty was associated with increased 
values of both glucose and insulin in girls, but only glucose in boys. Interestingly, in the cohort with 
overweight/obesity the associations between BMI SDS and both insulin and HOMA-IR were much 
higher per BMI SDS in pubertal than pre-pubertal girls and boys. These results suggest a greater 
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and more harmful effect of overweight and obesity on glucose metabolism after the onset of 
puberty. This is in line with the findings of a recent registry study of 62,565 Danish men, examining 
associations between weight status from childhood through early adulthood and risk of adult type 2 
diabetes 38. Bjerregaard et al. 38 found that childhood overweight at 7 years of age that remitted to 
normal weight at 13 years of age was associated with no increased risk of adult type 2 diabetes, 
whereas childhood overweight that continued into adolescence and early adulthood was associated 
with a fourfold increase in risk.  
Derangements in glucose metabolism often precede the development of type 2 diabetes. Although 
overt type 2 diabetes in childhood is relatively rare, prediabetes is common 6,8. Prediabetes 
constitutes a heterogeneous group of early alterations in glucose metabolism 5 and for this reason, 
there are several different criteria for the diagnosis. Diagnosing alternations in glucose metabolism 
in children and adolescents is further complicated by marked variations in normal values during 
growth and development. When obesity is also present, this natural variation is even more complex 
5,37. Our study demonstrated that pubertal insulin resistance occurs at an earlier age and either 
persists in girls or increases further in boys with overweight and obesity. The natural alterations in 
glucose metabolism, as well as the exaggerated alterations during childhood obesity, emphasize the 
importance of appropriate reference values. 
Established reference values are a useful tool for clinical assessment of children having increased 
risk of metabolic derangements and subsequent morbidity. Given the relative overlap between the 
presented cohorts and taking into consideration the complexity and relative heterogeneity of 
childhood obesity, no definitive single threshold can be given based on this data and accordingly, 
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individualized risk stratification should be done by taking the individual patients’ phenotype and 
biochemical marker into consideration. 
Strengths and limitations  
Insight into insulin resistance can be achieved in many ways. The gold standard measure of insulin 
resistance is obtained from clamp-studies 39, but this method is time consuming and not easily 
applicable in daily clinical practice. Therefore in the present study, fasting measures of plasma 
glucose and serum insulin were used, as well as HOMA-IR calculated from fasting values of 
glucose and insulin, as these measures have been shown to correlate with insulin sensitivity values 
obtained in clamp studies 24,40. 
Strengths of the present study include the large homogenous group of children and adolescents 
included, making the population-based cohort and the cohort with overweight/obesity comparable. 
Moreover, the biochemical methods were meticulous, as all samples were collected in a narrow 
time interval in the morning after an overnight fast. Additionally, all samples were analyzed at the 
same time and in the same batch using identical laboratory procedures for all participants. This is 
important as it has been shown that different assays for insulin measurement can produce important 
variations in concentrations 41.  
A limitation to the study is that only one blood sample was collected on each of the participants. 
Preferably, insulin would have been measured from blood samples taken at three consecutive time 
points to correct for the pulsatile insulin secretion. Likewise, with only a single measurement of 
glucose we were unable to adjust for natural day-to-day variation. Although the thorough 
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biochemical method would minimize this variation, and the fact that sampling and time of analysis 
was identical for all study participants allows for comparison. 
 
In conclusion, our study provides age- and sex-specific reference values for fasting blood 
concentrations of glucose, HbA1c, insulin, C-peptide, and the HOMA-IR index from a large 
population-based cohort of Danish/Northern European white children and adolescents. Markers of 
glucose metabolism vary during childhood and adolescence, increase transiently around puberty, 
and are dependent on age and sex. Children and adolescents with obesity exhibit increased 
concentrations of these biomarkers, especially after onset of puberty, which should raise awareness 
for both prevention and treatment of childhood obesity. 
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Tables  
Table 1. Descriptive information on the population-based cohort and the cohort with overweight/obesity 
 Population-based cohort Cohort with overweight/obesity 
Characteristic n  Median (interquartile range) n  Median (interquartile range) 
Age (years) 
                             f 
                             m 
1452 
999  
 
11.9 [9.3-15.0] 
11.0 [8.5-13.9] 
 
1050 
885  
 
11.7 [9.3, 14.4] 
11.9** [9.9, 13.8] 
Height (cm) 
                             f 
                             m 
 
1452 
999 
  
154.0 [137.0-165.5] 
148.5 [135.0-169.0] 
 
1050 
885 
  
154.2 [141.5, 164.5] 
155.0** [144.5, 167.0] 
Weight (kg) 
                             f 
                             m 
 
1452 
999 
  
43.5 [30.6-55.7] 
38.5 [29.3-56.2] 
 
1050 
885 
  
62.7** [47.3, 81.8] 
63.4** [50.0, 82.2] 
BMI SDS 
                             f 
                             m 
 
1452 
999 
  
0.2 [-0.5-1.0] 
0.3 [-0.4-1.0] 
 
1050 
885 
  
2.7** [2.3, 3.0] 
3.1** [2.6, 3.6] 
Puberty: pre-pubertal/ 
pubertal (%)         f 
                             m 
 
1161 
587 
  
32/68 
38/62 
 
893 
665 
 
 
 
34/66 
48/52 
Glucose (mmol/L) 
                             f 
                             m 
1413 
971  
 
4.9 [4.7-5.2] 
5.0 [4.8-5.2] 
1018 
861  
5.0** [4.7, 5.3] 
5.1** [4.9, 5.4] 
HbA1c (mmol/mol) 
                             f 
                             m 
 
1428 
974 
  
34.0 [32.0-35.0] 
34.0 [32.0-35.0] 
 
1043 
877 
  
34.0* [32.0, 36.0] 
34.0* [32.0, 36.0] 
Insulin (pmol/L)  
                             f 
                             m 
 
1440 
984 
  
61.6 [45.0-84.6] 
51.4 [34.1-68.8] 
 
1014 
863 
  
101.7** [70.1, 143.6] 
93.4** [63.2, 136.8] 
C-peptide (nmol/L) 
                             f 
                             m 
 
1421 
969 
  
0.6 [0.4-0.7] 
0.5 [0.4-0.6] 
 
976 
840 
  
0.8** [0.6, 1.1] 
0.8** [0.6, 1.0] 
HOMA-IR (mIU/L) 
                             f 
                             m 
 
1404 
960 
  
2.3 [1.6-3.2] 
1.9 [1.3-2.6] 
 
983 
840 
  
3.8** [2.5, 5.5] 
3.6** [2.4, 5.3] 
Data are medians and interquartile ranges. All biomarkers are fasting blood concentrations. BMI SDS: Body mass index standard 
deviation score; HbA1c: Hemoglobin A1c; HOMA-IR: Homeostasis model assessment: insulin resistance. * P<0.05 and ** 
P<0.001 compared with population-based cohort. 
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Table 2. Descriptive information by age group on the population-based cohort and the cohort with overweight/obesity 
 6.0-9.9 years 10.0-14.9 years 15.0-18.9 years 
 
Characteristic 
Population-
based cohort 
Cohort with 
overweight/obesity 
Population-
based cohort 
Cohort with 
overweight/obesity 
Population-
based cohort 
Cohort with 
overweight/obesity 
No. of Subjects 
                             f 
                             m 
 
481 
396 
 
326 
238 
 
610 
435 
 
523 
510 
 
361 
168 
 
201 
137 
Age (years) 
                             f 
                             m 
 
8.1 [7.1-9.2] 
8.0 [7.1-9.0] 
 
8.3* [7.5, 9.2] 
8.6** [7.6, 9.3] 
 
12.3 [11.2-13.5] 
12.3 [11.0-13.5] 
 
12.3 [11.1, 13.6] 
12.2 [11.3, 13.3] 
 
16.9 [15.9-17.9] 
16.8 [15.9-17.6] 
 
16.2** [15.5, 17.2] 
16.0** [15.5, 16.8] 
Height (cm) 
                             f 
                             m 
 
131.0 [124.5-138.4] 
132.0 [125.5-138.0] 
 
136.2** [130.7, 141.7] 
139.0** [132.0, 144.5] 
 
157.5 [150.0-164.0] 
156.0 [147.2-166.3] 
 
158.1 [150.9, 164.6] 
157.3 [150.8, 164.5] 
 
168.0 [164.0-172.0] 
179.9 [175.0-185.1] 
 
166.5* [163.5, 170.6] 
179.4 [173.5, 184.3] 
Weight (kg) 
                             f 
                             m 
 
27.7 [24.0-32.6] 
27.9 [24.7-31.7] 
 
41.8** [37.0, 47.7] 
45.5** [39.1, 52.8] 
 
45.4 [38.2-53.4] 
44.4 [37.2-53.8] 
 
68.7** [56.8, 81.0] 
65.8** [57.8, 76.2] 
 
59.5 [54.4-65.5] 
68.7 [62.4-76.8] 
 
89.3** [80.9, 99.5] 
108.3** [93.3, 122.1] 
BMI SDS 
                             f 
                             m 
 
0.2 [-0.5-1.0] 
0.2 [-0.5-1.0] 
 
2.7** [2.3, 3.0] 
3.4** [2.8, 4.0] 
 
0.2 [-0.5-0.9] 
0.3 [-0.4-1.1] 
 
2.7** [2.3, 3.0] 
2.9** [2.5, 3.4] 
 
0.4 [-0.3-0.9] 
0.5 [-0.0-1.1] 
 
2.8** [2.4, 3.2] 
3.4** [2.9, 3.7] 
Glucose (mmol/L) 
                             f 
                             m 
 
4.8 [4.6-5.0] 
4.9 [4.7-5.1] 
4.9** [4.7, 5.2] 
5.0** [4.7, 5.2] 
5.1 [4.9-5.3] 
5.1  [4.9-5.3] 
5.0 [4.8, 5.4] 
5.1 [4.9, 5.4] 
4.9 [4.6-5.1] 
5.1 [4.9-5.3] 
5.0* [4.7, 5.3] 
5.2** [5.0, 5.5] 
HbA1c (mmol/mol) 
                             f 
                             m 
 
34.0 [32.0-35.0] 
34.0 [32.0-35.0] 
 
34.0 [32.0, 36.0] 
34.0 [32.0, 36.0] 
 
34.0 [32.0-36.0] 
34.0 [32.0-36.0] 
 
34.0 [32.0, 36.0] 
34.0 [32.0, 36.0] 
 
33.0 [31.8-35.0] 
33.0 [31.0-35.0] 
 
33.0 [31.0, 36.0] 
34.0* [32.0, 36.0] 
Insulin (pmol/L) 
                             f 
                             m 
 
43.2 [30.8-56.2] 
34.5 [24.7-49.7] 
 
71.7** [52.1, 97.4] 
68.7** [48.6, 99.1] 
 
73.8 [55.4-97.0] 
60.3 [44.7-79.0] 
 
116.2** [84.4, 158.4] 
95.3** [68.8, 130.1] 
 
67.8 [53.9-89.4] 
60.0 [47.5-79.1] 
 
113.8** [82.2, 160.5] 
159.5** [114.6, 217.1] 
C-peptide (nmol/L) 
                             f 
 
0.4 [0.3-0.5] 
 
0.6** [0.5, 0.8] 
 
0.6 [0.5-0.8] 
 
0.9** [0.7, 1.2] 
 
0.7 [0.6-0.8] 
 
1.0** [0.8, 1.2] 
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                             m 0.4 [0.3-0.5] 0.6** [0.5, 0.7] 0.5 [0.4-0.7] 0.8** [0.6, 1.0] 0.6 [0.5-0.7] 1.1** [0.9, 1.4] 
HOMA-IR (mIU/L) 
                             f 
                             m 
 
1.6 [1.1-2.1] 
1.3 [0.9-1.8] 
 
2.6** [1.8, 3.7] 
2.6** [1.8, 3.6] 
 
2.8 [2.1-3.7] 
2.3 [1.7-3.1] 
 
4.5** [3.1, 6.2] 
3.7** [2.6, 5.0] 
 
2.5 [2.0-3.2] 
2.2 [1.8-3.1] 
 
4.3** [2.9, 6.2] 
6.0** [4.2, 8.7] 
Data are medians and interquartile ranges. All biomarkers are fasting blood concentrations. BMI SDS: Body mass index standard deviation score; HbA1c: Hemoglobin A1c; HOMA-IR: 
Homeostasis model assessment: insulin resistance. * P<0.05 and ** P<0.001 compared with same age group in the population-based cohort.  
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Legends to figures  
 
Figure 1. Percentile curves for fasting blood concentrations of glucose, Hemoglobin A1c (HbA1c), 
insulin, and Homeostasis model assessment: insulin resistance (HOMA-IR). Smoothed 5th, 50th, and 
95th percentile curves for girls (first column, red) and boys (second column, blue) from the 
population-based cohort. Individual values represented by light grey dots. 
 
Figure 2. Percentile curves for fasting blood concentrations of glucose, Hemoglobin A1c (HbA1c), 
insulin, and Homeostasis model assessment: insulin resistance (HOMA-IR). Smoothed 5th, 50th, and 
95th percentile curves for girls (first column, red) and boys (second column, blue). Full lines and 
light grey dots represent the population-based cohort, and dotted lines and dark grey dots represent 
the cohort with overweight/obesity. (Fourteen very high values from the cohort with 
overweight/obesity were outside depicted range: Girls, insulin: 694 pmol/L (10 years), 710 (11y), 
751 (12y), 941 (10y); Girls, HOMA-IR: 27 mIU/L (12y), 34 (10y), 35 (11y); Boys, insulin: 680 
(15y), 811 (12y), 1401 (16y), 2098 (14y); Boys, HOMA-IR: 28 (12y), 68 (16y), 101 (14y).) 
 
Supplementary Figure S1. Percentile curves for fasting blood concentrations of C-peptide. 
Smoothed 5th, 50th, and 95th percentile curves for girls (first column, red) and boys (second column, 
blue) from the population-based cohort (first row) and with the cohort with overweight/obesity 
superimposed (second row). Full lines and light grey dots represent the population-based cohort, 
and dotted lines and dark grey dots represent the cohort with overweight/obesity. (Three very high 
values from the cohort with overweight/obesity were outside depicted range: Girls: 3.3 nmol/L (12 
years); Boys: 3.9 (16y), 5.1 (14y).) 
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